This page shows the latest chronic low back pain news and features for those working in and with pharma, biotech and healthcare.
The 16-week study in patients with osteoarthritis (OA) pain evaluated subcutaneous administration of tanezumab, one of a new class of nerve growth factor (NGF) inhibitor drugs. ... In addition to OA pain, the biologic is being evaluated for chronic low
pain. The US FDA gave the status to tanezumab as a treatment for osteoarthritis and chronic low back pain in patients who cannot adequate pain relief or cannot tolerate currently available ... potential. They estimate that there are more than 27 million
The FDA placed a clinical hold on a phase IIb trial of Teva and Regeneron's nerve growth factor (NGF) inhibitor fasinumab in chronic lower back pain on safety concerns. ... We look forward to working with global health authorities to advance this
pegged back by the termination of a collaboration with Boehringer Ingelheim on chronic obstructive pulmonary disease (COPD) treatment Spiriva (tiotropium) in some markets. ... The company has also joined forces with Lilly to develop anti-nerve growth
osteoarthritis and chronic lower back pain. ... The marketing application for the latest indication was supported by relatively small clinical studies enrolling about 600 patients with chronic low back pain or chronic pain due to osteoarthritis who
broader population after reviewing safety and efficacy data from studies testing the drug for chronic low back pain and for chronic pain due to osteoarthritis of the knee. ... For people living with chronic low back pain and chronic pain due to
More from news
Approximately 1 fully matching, plus 7 partially matching documents found.
prostate cancer. 2, 400. Pfizer / Lilly. Co-development. Shared development of tanezumab (anti-nerve growth factor) for the treatment of osteoarthritis, chronic low back and cancer pain. ... hyperactivity disorder, pain, urology and allergy. 1, 600.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...